Form 4: Tarsus Pharmaceuticals COO Neervannan Seshadri Reports Stock Option and Restricted Stock Unit Grant
SEC Filing (Form 4)
Chief Operating Officer of Tarsus Pharmaceuticals, Neervannan Seshadri, reports the acquisition of stock options and restricted stock units.
Summary
- Neervannan Seshadri, the Chief Operating Officer of Tarsus Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports the grant of stock options to purchase 47,500 shares of common stock at an exercise price of $35.50 on March 7, 2024.
- These options vest 25% on March 7, 2025, and then 1/48th monthly for the following three years, contingent upon continuous service.
- Seshadri also received 32,079 restricted stock units (RSUs) on March 7, 2024.
- These RSUs vest 25% on March 15th of each year from 2025 to 2028, also subject to continuous service.
- Each RSU represents the right to receive one share of Tarsus Pharmaceuticals common stock.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which are generally viewed neutrally to positively as they align management interests with shareholders.
Positives
- The grant of stock options and RSUs aligns the COO's interests with those of the shareholders, incentivizing him to drive company performance.
- The vesting schedules encourage long-term commitment from the COO.
Industry Context
Stock option and RSU grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, similar to companies like Bausch + Lomb or Novartis.
- The vesting schedules described are typical, aligning with industry norms for incentivizing long-term performance.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize management to increase shareholder value.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of stock option and RSU grant |
| 03/07/2025 | First vesting date for 25% of stock options |
| 03/15/2025 | First vesting date for 25% of RSUs |
| 03/06/2034 | Expiration date of stock options |
| 03/11/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.